| Dacia R Gerst, FNP | |
|
409 W Oak St, Carbondale, IL 62901-1464 | |
| (618) 529-4455 | |
| (618) 351-1287 |
| Full Name | Dacia R Gerst |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 20 Years |
| Location | 409 W Oak St, Carbondale, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104874338 | NPI | - | NPPES |
| P00303539 | Other | RR MEDICARE HEARTLAND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 209005199 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern Illinois Medical Services Nfp | 3678677390 | 254 |
News Archive
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.
Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
› Verified 8 days ago
| Entity Name | Prairie Cardiovascular Consultants Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982714218 PECOS PAC ID: 3173435880 Enrollment ID: O20031103000090 |
News Archive
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.
Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
› Verified 8 days ago
| Entity Name | Prairie Cardiovascular Consultants Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982714218 PECOS PAC ID: 3173435880 Enrollment ID: O20031230000311 |
News Archive
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.
Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
› Verified 8 days ago
| Entity Name | Southern Illinois Medical Services Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770656837 PECOS PAC ID: 3678677390 Enrollment ID: O20070404000595 |
News Archive
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.
Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dacia R Gerst, FNP Po Box 3988, Carbondale, IL 62902-3988 Ph: (618) 457-5200 | Dacia R Gerst, FNP 409 W Oak St, Carbondale, IL 62901-1464 Ph: (618) 529-4455 |
News Archive
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.
Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.
For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning.
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
› Verified 8 days ago
Miss Whitney Mcguire, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 305 W Jackson St Ste 103, Carbondale, IL 62901 Phone: 618-351-4972 Fax: 618-351-6522 | |
Ashley Nicole Mitchell, APRN, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2601 W Main St, Carbondale, IL 62901 Phone: 618-549-5361 Fax: 618-351-4878 | |
Natasha Charlyn Shafer, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1340 Cedar Ct Ste 202, Carbondale, IL 62901 Phone: 618-529-7821 | |
Mrs. Jennifer Sue Campos, FNP-BC, CCRN, CMC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 405 W Jackson St, Carbondale, IL 62901 Phone: 618-549-0721 | |
Lindsay B Casolari, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2601 W Main St, Carbondale, IL 62901 Phone: 618-549-5361 Fax: 618-351-4878 | |
Ms. Heather Dawn Davis, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 305 W Jackson St Ste 206, Carbondale, IL 62901 Phone: 618-457-3006 Fax: 618-457-3008 | |
Andrea Williams, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2601 W Main St, Carbondale, IL 62901 Phone: 618-549-5361 Fax: 618-351-4878 |